These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24906398)

  • 1. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Tsuda M; Ishiguro H; Yano I; Toi M
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
    [No Abstract]   [Full Text] [Related]  

  • 2. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Adhikaree J; Newby Y; Sundar S
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
    [No Abstract]   [Full Text] [Related]  

  • 3. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
    J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response.
    Glezerman IG; Hu MI; Jain RK
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906399
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
    Dawson C; Todd AM; Walton A
    J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
    Jilani A; Garrett Z; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Dec; 13(12):1194-5. PubMed ID: 23323278
    [No Abstract]   [Full Text] [Related]  

  • 7. [Management of bone metastases].
    Nagykálnai T; Landherr L
    Orv Hetil; 2014 Feb; 155(6):217-25. PubMed ID: 24486845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
    Boikos SA; Hammers HJ
    J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
    [No Abstract]   [Full Text] [Related]  

  • 10. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological management of skeletal-related events from metastatic tumors.
    Hitron A; Adams V
    Orthopedics; 2009 Mar; 32(3):188. PubMed ID: 19309055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
    Adhikaree J; Newby Y; Sundar S
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials.
    Araki K; Ito Y; Takahashi S
    Eur J Cancer; 2013 Jun; 49(9):2264-5. PubMed ID: 23541567
    [No Abstract]   [Full Text] [Related]  

  • 18. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
    Lin PH; Chiu CF; Lu YS
    Ann Oncol; 2011 May; 22(5):1244-1246. PubMed ID: 21460375
    [No Abstract]   [Full Text] [Related]  

  • 19. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
    Kohno N
    Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in diagnosis and therapy: Hypercalcemia due to multiple myeloma and wide-spread neoplastic bone metastasis].
    Abe M
    Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):675-80. PubMed ID: 17506303
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.